Sort   by:  
 Page size 
ProteomicsUninfected and human respiratory syncytial virus (RSV)-infected A549 cells, analysed using bottom-up mass spectrometry
Proteomic data from uninfected and human respiratory syncytial virus (RSV) infected A549 cells (24h post infection; four biological replicate sets). Data is related to the fractionation-free workflow described in Dave et al. (2014) (PMID: 25106423). Data is processed using MaxQuant (version 1.3.0.5)...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) Human Respiratory Syncytial Virus A2 (ncbitaxon:11259) 
2016-08-08 | MSV000080032 | MassIVE
ProteomicsUninfected and human respiratory syncytial virus (RSV)-infected A549 cells, analysed using in-solution protein IEF followed by bottom-up mass spectrometry
Proteomic data from uninfected and human respiratory syncytial virus (RSV)-infected A549 cells (24h post infection; five paired biological replicate sets). Data is related to the in-solution protein IEF workflow described in Dave et al. (2014) (PMID: 25106423). Data processed using MaxQuant (version...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) Human Respiratory Syncytial Virus A2 (ncbitaxon:11259) 
2016-01-12 | MSV000079453 | MassIVE
ProteomicsProteomic changes occurring in Anopheles gambiae and Anopheles stephensi during aging
The age of mosquitoes is a crucial determinant of their susceptibility to infection, probability of survival to transmit pathogens and tolerance to insecticides. We investigated changes to the abundance of proteins found in heads and thoraces of Anopheles gambiae and Anopheles stephensi as they aged...
ORGANISM(S): Anopheles gambiae (African malaria mosquito) Anopheles stephensi (Asian malaria mosquito) 
2015-08-26 | PXD002153 | Pride
Proteomics Anopheles gambiae Mass spectrometry Mosquito Anopheles stephensi Malaria Maldi Orbitrap Ageing 
ProteomicsIdentification of proteins deregulated by platinum-based chemotherapy as novel biomarkers and therapeutic targets in non-small cell lung cancer
Platinum-based chemotherapy remains the cornerstone of treatment for most people with non-small cell lung cancer (NSCLC), either as adjuvant therapy in combination with a second cytotoxic agent or in combination with immunotherapy. Resistance to therapy, either in the form of primary refractory dise...
ORGANISM(S): Homo Sapiens 
2021-06-15 | PXD024209 | panorama
Sort   by:  
 Page size